Lundbeck CDM delivers end-to-end API and drug product solutions from development to commercial scale.

Reset all filters
01 1Bendeka And Trenda
02 5Bendeka and Trenda
03 1Bendeka/Trenda
04 3Treakisym
05 2Treakisym/Symbenda
06 3Treanda
07 1Treanda And Bendeka
08 1Treanda and Bendeka
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 64%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 496
2018 Revenue in Millions : 642
Growth (%) : -23

Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 68
2019 Revenue in Millions : 71
Growth (%) : -4

Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 415
2019 Revenue in Millions : 496
Growth (%) : -16

Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 385
2020 Revenue in Millions : 415
Growth (%) : -7

Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 44
2020 Revenue in Millions : 66
Growth (%) : -28

Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 316
2021 Revenue in Millions : 385
Growth (%) : -18

Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 241
2022 Revenue in Millions : 316
Growth (%) : -24

Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 168
2023 Revenue in Millions : 237
Growth (%) : -29

Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 8.20%
2013 Revenue in Millions :
Growth (%) :




